Bionano Sets 2026 Outlook After $8 Million Q4 and Sharper Margins

Overview

• Bionano reported Q4 2025 revenue of $8.0 million and full‑year revenue of $28.5 million, and guided 2026 revenue to $30–$33 million with Q1 at $6.5–$6.7 million.
• The company is shifting from adding systems to selling more consumables and software to routine users of its optical genome mapping tests, a lab method to find large DNA changes across the genome.
• Medicare created a new billing code for OGM in constitutional disorders and raised the OGM hematology payment 47% to $1,853, which could make payer coverage and lab adoption easier.
• Non‑GAAP gross margin reached 47% for 2025 and non‑GAAP operating expense fell 47%, and with $29.6 million in cash and planned retirement of secured convertible debt in May 2026 the company projects a runway into 2027.
• A late‑quarter delay at a silicon wafer supplier limited chip output and created a consumables backlog that management expects to ship as supply improves in 2026.